ASH 2018 | Progress for gilteritinib and quizartinib for AML in the first-line setting
The FLT3 inhibitors quizartinib and gilteritinib have made great progress in the relapsed/refractory acute myeloid leukemia (AML) space; however, they may be able to exert more of a benefit in the upfront setting, as discussed here by Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Dr Levis highlights the progress in the first-line setting for both of these drugs. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up